Lincoln Pharmaceuticals Ltd

As of June 30, 2026, Lincoln Pharmaceuticals Ltd carries a market capitalization of 12.49B, placing it among publicly traded companies globally. Its enterprise value stands at 12.49B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Lincoln Pharmaceuticals Ltd has 20.03M shares outstanding.

As of June 30, 2026, Lincoln Pharmaceuticals Ltd trades at a trailing price-to-earnings ratio of 12.95.

As of June 30, 2026, Lincoln Pharmaceuticals Ltd trades at an EV/EBITDA multiple of 12.33 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.80 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 14.45 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 12.49B versus a market cap of 12.49B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 4.33M in revenue per employee across its workforce of 1,602.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Lincoln Pharmaceuticals Ltd recorded 313.37M in income tax expense. That works out to an effective tax rate of 24.52, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 1.28B, leaving 964.53M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Lincoln Pharmaceuticals Ltd's stock has declined approximately 3.16% over the past 52 weeks. The 50-day moving average sits at 593.43, while the 200-day moving average is 591.99.

Over the twelve months ended June 30, 2026, Lincoln Pharmaceuticals Ltd generated 6.94B in revenue and converted that into 964.53M in net income, yielding earnings per share of 48.16. EBITDA reached 1.01B, while operating income came in at 864.05M.

Over the twelve months ended June 30, 2026, Lincoln Pharmaceuticals Ltd posted a gross margin of 52.91, reflecting its pricing power and cost economics. The operating margin of 12.45 and net profit margin of 13.89 provide insight into operational efficiency.

Lincoln Pharmaceuticals Ltd's most recent stock split took place on March 19, 2009 with a 5:1 split ratio.